Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q1 Revenues Jump 140 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics this week reported first-quarter 2010 revenue growth of 140 percent, driven by its Response DX test sales.

The Los Angeles, Calif.-based molecular diagnostics firm had total revenues of $3.7 million for the three-month period ended March 31, compared to $1.5 million for the first quarter of 2009. It said that sales of its Response DX genetic tests rose to $1.72 million from $263,000 for the first quarter of 2009.

Response Genetics posted a net loss of $2.1 million, or $.13 per share, for the quarter, down sharply from $3.3 million, or $.30 per share.

Its R&D costs edged up to $572,184 from $554,238 year over year, while its SG&A spending rose to $3.1 million from $2.5 million.

Response Genetics finished the quarter with $9.1 million in cash and cash equivalents.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.